TY - JOUR
T1 - Use of oral anticoagulants in patients with valvular atrial fibrillation
T2 - findings from the NCDR PINNACLE Registry
AU - Hess, Paul L.
AU - Gosch, Kensey L.
AU - Jani, Sandeep M.
AU - Varosy, Paul D.
AU - Bradley, Steven M.
AU - Maddox, Thomas M.
AU - Michael Ho, P.
AU - Virani, Salim S.
N1 - Funding Information:
Dr. Hess receives grant support from the VA Career Development Award #HX002621 from the US Department of Veterans Affairs Health Services & Research Development Service and Career Development Award #19CDA347670126 from the American Heart Association. Dr. Maddox discloses current grant funding from the NIH NCATS (1U24TR002306-01: A National Center for Digital Health Informatics Innovation) and honoraria and/or expense reimbursement in the past 3 years from New York Presbyterian (September 2017), Westchester Medical Center (October 2017), Sentara Heart Hospital (December 2018), the Henry Ford health system (March 2019), and the University of California San Diego (January 2020). He is currently employed as a cardiologist and the executive director of the Healthcare Innovation Lab at BJC HealthCare/Washington University School of Medicine. In this capacity, he is advising Myia Labs, for which his employer is receiving equity compensation in the company. He is receiving no individual compensation from the company. He is also a compensated director for a New Mexico-based foundation, the J.F. Maddox Foundation. Dr. Ho receives grant support from the Department of Veterans Affairs; the National Heart, Lung, and Blood Institute; and the University of Colorado School of Medicine. He has a research agreement with Bristol-Myers Squibb through the University of Colorado School of Medicine. He serves as Deputy Editor of Circulation: Cardiovascular Qulaity and Outcomes. Dr. Virani receives grant support from the Department of Veterans Affairs, the World Heart Federation, and the Tahir and Jooma Family. He has received honoraria from the American College of Cardiology as Associate Editor for Innovations on acc.org.
Publisher Copyright:
© 2021
PY - 2021/10
Y1 - 2021/10
N2 - Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.
AB - Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.
UR - http://www.scopus.com/inward/record.url?scp=85109497162&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2021.04.017
DO - 10.1016/j.ahj.2021.04.017
M3 - Letter
C2 - 34033802
AN - SCOPUS:85109497162
SN - 0002-8703
VL - 240
SP - 58
EP - 62
JO - American heart journal
JF - American heart journal
ER -